reports
- Martin Hall
Hardman & Co Healthcare Index: 2023 – Capital demands dent performance
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ETX E-THERAPEUTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
APH ALLIANCE PHARMA PLC
AVO ADVANCED ONCOTHERAPY
OXB OXFORD BIOMEDICA PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
SN/ IMMUPHARMA
IMM PROTEOME SCIENCES PLC
PRM GENUS PLC
GNS SURGICAL INNOVATIONS GROUP PLC
SUN ADVANCED MEDICAL SOLUTIONS GROUP PLC
AMS OXFORD METRICS
OMG ECO ANIMAL HEALTH GROUP
EAH SDI GROUP
SDI HVIVO
HVO INDIVIOR PLC
INDV VALIRX
VAL SHIELD THERAPEUTICS
STX SYNAIRGEN PLC
SNG IP GROUP
IPO SCANCELL HOLDINGS
SCLP SYNCONA
SYNC ERGOMED
ERGO SPIRE HEALTHCARE GROUP PLC
SPI REDX PHARMA
REDX ASSURA PLC
AGR GENEDRIVE
GDR SPIRE INC
SR CONVATEC GROUP PLC
CTEC DESTINY PHARMA
DEST RENEURON GROUP
RENE IXICO
IXI 10X GENOMICS INC CLASS A
TXG INDIVA LTD
NDVA IMMUNOCORE HOLDINGS ADS
IMCR 2SEVENTY BIO INC
TSVT OXFORD NANOPORE TECHNOLOGIES PLC
ONT SILENCE THERAPEUTICS PLC
SLN SAREUM HOLDINGS PLC
SAR BENEVOLENTAI
BAI 123FAHRSCHULE SE
123F 1895 BANCORP OF WISCONSIN INC
BCOW TISSUE REGENIX GROUP PLC
PLP.H 3D SIGNATURES INC
Z29 029 GROUP SE
Hybridan Small Cap Feast - 11 Oct 23
11th October 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje...
Hybridan Small Cap Feast - 27 Apr 23
27th April 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object...
Synairgen announces its inhaled interferon beta (SNG001) is advancing ...
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, has been informed that the external data...
Interim results for the six months ended 30 June 2021
Interim results for the six months ended 30 June 2021 Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, today announces its unaudited interim results for the six months ended 30 June 2021. Richard Marsden, CEO of Synairgen, said: “The need for an effective, broad-spectrum antiviral to treat patients hospitalised due to CO...
Non-Executive Director Appointment
Non-Executive Director Appointment Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, is pleased to announce the appointment of Theodora Harold as an independent Non-Executive Director of the Company and Chair of the Audit Committee with immediate effect. Theodora has over 20 years’ experience in the biotech sector and is currently CEO of Crescendo Biologics Ltd. She was previously part of the founding management teams of both PsiOxus T...
Non-Executive Director Appointment
Non-Executive Director Appointment Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, is pleased to announce the appointment of Theodora Harold as an independent Non-Executive Director of the Company and Chair of the Audit Committee with immediate effect. Theodora has over 20 years’ experience in the biotech sector and is currently CEO of Crescendo Biologics Ltd. She was previously part of the founding management teams of both PsiOxus T...
Interim results for the six months ended 30 June 2021
Interim results for the six months ended 30 June 2021 Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, today announces its unaudited interim results for the six months ended 30 June 2021. Richard Marsden, CEO of Synairgen, said: “The need for an effective, broad-spectrum antiviral to treat patients hospitalised due to CO...
Synairgen announces results of in vitro studies showing antiviral acti...
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001 shows potent antiviral activity against SARS-CoV-2 variantsDemonstrates broad-spectrum antiviral activity of host-targeted antiviral treatment delivered directly into the lungs Southampton, UK – 24 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing...
Synairgen announces results of in vitro studies showing antiviral acti...
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001 shows potent antiviral activity against SARS-CoV-2 variantsDemonstrates broad-spectrum antiviral activity of host-targeted antiviral treatment delivered directly into the lungs Southampton, UK – 24 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing...
Preliminary results for the year ended 31 December 2020
Preliminary results for the year ended 31 December 2020 Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 Southampton, UK – 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post period-end) Operational P...
Preliminary results for the year ended 31 December 2020
Preliminary results for the year ended 31 December 2020 Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2020 Significant progress continues towards a treatment for COVID-19 Southampton, UK – 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post period-end) Operational Positive results from Synairg...
Synairgen announces data from Home Cohort of SG016 Phase II trial of i...
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial The vast majority of Home Cohort patients experienced mild disease - only two patients were hospitalised during the treatment period, both on placeboHome Cohort patients successfully self-administer...
Synairgen announces data from Home Cohort of SG016 Phase II trial of i...
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial The vast majority of Home Cohort patients experienced mild disease - only two patients were hospitalised during the treatment period, both on placeboHome Cohort patients successfully self-administer...
Synairgen announces that dosing has commenced with its inhaled interfe...
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta f...
Synairgen announces that dosing has commenced with its inhaled interfe...
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta f...
Synairgen announces inclusion of its inhaled interferon beta treatment...
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19 Southampton, UK – 25 January 2021: Synairgen plc (LSE: SNG), the ...
Synairgen announces inclusion of its inhaled interferon beta treatment...
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19 Southampton, UK – 25 January 2021: Synairgen plc (LSE: SNG), the ...
Synairgen announces completion of recruitment into its Phase II Home-B...
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta - Establishing proof of concept for home administration Southampton, UK – 20 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 120 COVID-19 patients into its Phase II trial evaluating inhaled formulation of in...
Synairgen announces completion of recruitment into its Phase II Home-B...
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta - Establishing proof of concept for home administration Southampton, UK – 20 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that recruitment of 120 COVID-19 patients into its Phase II trial evaluating inhaled formulation of in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.